Text Size

Fanconi Anemia Transplant Lacking Genotypically Identical Donor

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Children's Hospital Boston.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Dana-Farber Cancer Institute
Information provided by:
Children's Hospital Boston
ClinicalTrials.gov Identifier:
NCT00850317
First received: February 24, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
  Purpose

A research study for patients with Fanconi Anemia whose bone marrow has changed and now failed, giving rise to a pre-leukemia or leukemia. This study is a Phase II clinical trial in which patients will undergo allogenic transplant of stem cells, meaning they will receive bone marrow cells from a healthy donor. The purpose of this study is to see if transplant course of treatment will lower the risk of graft vs. host disease.


Condition Intervention Phase
Fanconi Anemia
 Device: Miltenyi CliniMACs device
 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter Phase II Trial-Hematopoietic Stem Cell Transplantation for Treatment of Patients With FA Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

Resource links provided by NLM:

MedlinePlus related topics: Anemia
U.S. FDA Resources

Further study details as provided by Children's Hospital Boston:

Primary Outcome Measures:
  • the incidence and quality of engraftment and hematopoietic reconstitution, the incidence of early transplant related mortality, the incidence and severity of acute GvHD and chronic GVHD. [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The occurrence of severe post transplant regimen-related severe morbidity (grade III/IV toxicity) and/or mortality [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 25
Study Start Date: April 2009
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Reduced-intensity transplant with non-TBI containing regimen for Fanconi ANemia
 Device: Miltenyi CliniMACs device
CD34 selection

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis: Patients must have a diagnosis of Fanconi anemia (confirmed by mitomycin C or diepoxybutane [DEB] chromosomal breakage testing at an approved laboratory)

  • Hematologic Diagnosis and Status: Patients must have one of the following hematologic diagnoses:

    1. Severe Aplastic Anemia (SAA), or Severe Isolated Single lineage

      Cytopenia with bone marrow cellularity of < 25% AND at least one of the following features:

      • Platelet count < 20 x 109/L or platelet transfusion dependence
      • ANC < 1000 x 109/L
      • Hgb < 8 gm/dl or red cell transfusion dependence

    2. Myelodysplatic Syndrome (MDS) (Appendix 1: MDS Classification). MDS at any stage, based on either one of the following classifications:

      • WHO Classification
      • Refractory anemia and transfusion dependence
      • Any of other stages
      • IPSS Classification
      • Low risk (score 0) and transfusion dependence
      • Any other risk groups Score > 0.5
    3. Acute Myelogenous Leukemia: Patients with acute leukemia are included in this trial in remission, refractory or relapsed disease

Exclusion Criteria:

  • Active CNS leukemic involvement
  • Female patients who are pregnant or breast-feeding
  • Active uncontrolled viral, bacterial or fungal infection
  • Patient seropositive for HIV-I/II; HTLV -I/II
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00850317

Locations
United States, Massachusetts
Dana-Farber Cancer Institute Not yet recruiting
Boston, Massachusetts, United States, 02115
Contact: Amber Smith     617-355-3748     amber.smith@childrens.harvard.edu    
Contact: Deborah Chirnomas, M.D.     617-632-6798     deborah_chirnomas@dfci.harvard.edu    
Principal Investigator: David A Williams, M.D.            
Sub-Investigator: Deborah Chirnomas, M.D.            
Sponsors and Collaborators
Children's Hospital Boston
Dana-Farber Cancer Institute
Investigators
Principal Investigator: David A Williams, MD Children's Hospital Boston
  More Information

No publications provided

Responsible Party: David A. Williams, MD, Children's Hospital Boston and Dana Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT00850317     History of Changes
Other Study ID Numbers: 08-377
Study First Received: February 24, 2009
Last Updated: February 24, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Children's Hospital Boston:
Fanconi Anemia
FA
Stem Cell Transplant
T-Cell

Additional relevant MeSH terms:
Anemia
Fanconi Anemia
Fanconi Syndrome
Hematologic Diseases
Anemia, Hypoplastic, Congenital
Anemia, Aplastic
Bone Marrow Diseases
 Genetic Diseases, Inborn
DNA Repair-Deficiency Disorders
Metabolic Diseases
Kidney Diseases
Urologic Diseases
Renal Tubular Transport, Inborn Errors
Metabolism, Inborn Errors

ClinicalTrials.gov processed this record on May 23, 2013